loading
Schlusskurs vom Vortag:
$0.97
Offen:
$0.97
24-Stunden-Volumen:
15,833
Relative Volume:
0.02
Marktkapitalisierung:
$6.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.52%
1M Leistung:
-27.78%
6M Leistung:
+55.93%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$0.921
$0.9949
1-Wochen-Bereich:
Value
$0.9096
$1.05
52-Wochen-Spanne:
Value
$0.45
$3.80

Chromocell Therapeutics Corp Stock (CHRO) Company Profile

Name
Firmenname
Chromocell Therapeutics Corp
Name
Telefon
(917) 644-6313
Name
Adresse
685 US HIGHWAY ONE, NORTH BRUNSWICK
Name
Mitarbeiter
7
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CHRO's Discussions on Twitter

Vergleichen Sie CHRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CHRO
Chromocell Therapeutics Corp
0.985 6.79M 0 0 0 0.00
Biotechnology icon
ONC
Beigene Ltd Adr
240.01 25.61B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.30 114.83B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.29 41.82M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
593.42 66.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.78 6.36B 0 -153.72M -103.81M -2.00

Chromocell Therapeutics Corp Aktie (CHRO) Neueste Nachrichten

pulisher
May 01, 2025

Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan

May 01, 2025
pulisher
Apr 17, 2025

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.

Apr 17, 2025
pulisher
Mar 03, 2025

Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia

Mar 03, 2025
pulisher
Mar 03, 2025

Channel Therapeutics secures $325,000 promissory note - Investing.com India

Mar 03, 2025
pulisher
Feb 28, 2025

New Biotech Stocks at Investorideas.com - Investorideas.com newswire

Feb 28, 2025
pulisher
Jan 21, 2025

Wall Street-Heavily Traded - WDRB

Jan 21, 2025
pulisher
Jan 14, 2025

Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online

Jan 14, 2025
pulisher
Dec 20, 2024

Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan

Dec 20, 2024
pulisher
Dec 18, 2024

Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan

Dec 18, 2024
pulisher
Nov 23, 2024

Chromocell Therapeutics Announces Name Change to Channel Therapeutics Corporation and Provides Therapeutic Program Updates - Defense World

Nov 23, 2024
pulisher
Nov 21, 2024

Chromocell Announces Name Change to 'Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - The Manila Times

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell changes name to Channel Therapeutics, provides program updates - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

Channel Therapeutics Corporation Provides Therapeutic Program Update - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Certain Warrants of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation announces an Equity Buyback for $0.25 million worth of its shares. - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation announced that it expects to receive $0.75 million in funding - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation announced that it has received $0.75 million in funding - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024
pulisher
Nov 19, 2024

Channel Therapeutics finalizes corporate restructuring By Investing.com - Investing.com Canada

Nov 19, 2024
pulisher
Nov 19, 2024

Channel Therapeutics finalizes corporate restructuring - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Channel Therapeutics announces corporate restructuring - Investing.com

Nov 19, 2024
pulisher
Oct 29, 2024

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

Chromocell to Present at Upcoming Fall Investor Conferences - StockTitan

Oct 28, 2024
pulisher
Oct 25, 2024

Chromocell Therapeutics amends stock repurchase plan - TradingPedia

Oct 25, 2024
pulisher
Oct 24, 2024

Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan

Oct 24, 2024
pulisher
Oct 18, 2024

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Oct 18, 2024
pulisher
Sep 20, 2024

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire

Sep 20, 2024
pulisher
Sep 17, 2024

Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra

Sep 17, 2024
pulisher
Sep 16, 2024

Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance

Sep 16, 2024
pulisher
Sep 11, 2024

CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online

Sep 11, 2024
pulisher
Sep 10, 2024

IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online

Sep 10, 2024
pulisher
Aug 07, 2024

Tranche Update on Channel Therapeutics Corporation's Equity Buyback Plan announced on August 7, 2024. - Marketscreener.com

Aug 07, 2024
pulisher
Apr 23, 2024

Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC

Apr 23, 2024
pulisher
Apr 19, 2024

Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView

Apr 19, 2024
pulisher
Apr 09, 2024

Chromocell Issues Letter to Stockholders from Chief Executive Officer - StockTitan

Apr 09, 2024
pulisher
Mar 22, 2024

Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech

Mar 22, 2024
pulisher
Mar 19, 2024

Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine

Mar 19, 2024
pulisher
Mar 12, 2024

Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance

Mar 12, 2024
pulisher
Feb 21, 2024

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Stock Titan

Feb 21, 2024
pulisher
Feb 16, 2024

CHRO Stock Price and Chart — AMEX:CHRO - TradingView

Feb 16, 2024
pulisher
Feb 16, 2024

CHROChannel Therapeutics Corporation Latest Stock News & Market Updates - StockTitan

Feb 16, 2024
pulisher
Jan 16, 2024

Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com

Jan 16, 2024

Finanzdaten der Chromocell Therapeutics Corp-Aktie (CHRO)

Es liegen keine Finanzdaten für Chromocell Therapeutics Corp (CHRO) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price up icon 0.00%
$31.02
price down icon 0.96%
$579.77
price down icon 1.33%
$290.05
price up icon 0.45%
$4.28
price up icon 0.71%
$75.61
price up icon 0.73%
Kapitalisierung:     |  Volumen (24h):